This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Huse, D. M. Articles by Abdalla, J. A. Search for Related Content PubMed PubMed Citation Articles by Huse, D. M. Articles by Abdalla, J. A. Social Bookmarking                   What's this?

Patterns of Initial Pharmacotherapy for Parkinson’s Disease in the United States

Thomson Medstat, Cambridge, MA, Dan.Huse{at}thomson.com

Jane Castelli-Haley, MBA

Teva Neuroscience, Kansas City, MO

Lucinda S. Orsini, DPM, MPH

Thomson Medstat, Cambridge, MA

Gregory Lenhart, MS

Thomson Medstat, Cambridge, MA

Judith A. Abdalla, MD

Teva Neuroscience, Kansas City, MO

Data from a mix of employer- and government-funded health plans were used to investigate actual treatment patterns for patients initiating pharmacotherapy for Parkinson’s disease in the United States. Treatment patterns evaluated included type of initial therapy and rates and types of adjunctive and substitute therapies. The study confirms that levodopa remains the most often prescribed initial treatment for Parkinson’s disease regardless of age or drug benefit coverage. The widespread use of levodopa in young Parkinson’s patients (<65 years) with private insurance may indicate that physicians are not overly concerned about or are not fully aware of the association of levodopa with long-term motor complications. It may also indicate that currently available alternatives to levodopa are not sufficiently effective or well tolerated.

Key Words: Parkinson’s disease • pharmacotherapy • prescribing patterns • levodopa

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?